Compare MAIA & ANTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MAIA | ANTA |
|---|---|---|
| Founded | 2018 | 2022 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.0M | 90.3M |
| IPO Year | 2022 | 2024 |
| Metric | MAIA | ANTA |
|---|---|---|
| Price | $1.36 | $3.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $16.17 |
| AVG Volume (30 Days) | ★ 443.8K | 7.7K |
| Earning Date | 05-12-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $21.95 |
| Revenue Next Year | N/A | $30.46 |
| P/E Ratio | ★ N/A | $19.77 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $3.00 |
| 52 Week High | $3.19 | $13.82 |
| Indicator | MAIA | ANTA |
|---|---|---|
| Relative Strength Index (RSI) | 49.02 | 43.69 |
| Support Level | $1.24 | $3.39 |
| Resistance Level | $1.48 | $4.19 |
| Average True Range (ATR) | 0.07 | 0.33 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 34.83 | 19.35 |
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.
Antalpha Platform Holding Co provides financing, technology and risk management solutions to institutional and corporate customers in the crypto asset industry. The company operates through Antalpha Prime platform in the following areas: Supply chain financing and Technology and services. Its revenue prominently consists of technology financing fees charged on the supply chain loans.